Ter Meer Und Partner patent opposition analysis

The comprehensive analysis of Ter Meer Und Partner opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Ter Meer Und Partner

Patent NumberTitleApplicantOpposition DateOpposition Company
High Concentration Vegf Receptor Fusion Protein Containing FormulationsREGENERON PHARMACEUTICALSAug 24, 2026INTAS PHARMACEUTICALS
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHME LLCJul 22, 2026ABBOTT PRODUCTION OPERATIONS
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL-MYERS SQUIBB COMPANYJul 13, 2026MANZER

Top companies who are the clients of Ter Meer Und Partner